Potential utility of urinary chemokine CCL2 to creatinine ratio in prognosis of 5-year graft failure and mortality post 1-year protocol biopsy in kidney transplant recipients.
CCL2
chemokines
kidney transplant
Journal
Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
16
05
2023
received:
08
12
2022
accepted:
16
05
2023
medline:
30
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Chemokines (chemotactic cytokines) are small proteins which are engaged in many pathophysiological processes, including inflammation and homeostasis. In recent years, application of chemokines in transplant medicine was intensively studied. The aim of this study was to determine the utility of urinary chemokines CCL2 (C-C motif ligand 2) and CXCL10 (C-X-C motif chemokine ligand 10) in prognosis of 5-year graft failure and mortality post 1-year protocol biopsy in renal transplant recipients. Forty patients who had a protocol biopsy 1 year after renal transplantation were included. Concentrations of CCL2 and CXCL10 in urine with reference to urine creatinine were measured. All patients were under the supervision of one transplant center. Long-term outcomes within 5 years after 1-year posttransplant biopsy were analyzed. Urinary CCL2:Cr at the time of biopsy was significantly increased in patients who died or had graft failure. CCL2:Cr was proven to be a significant predictor of 5-year graft failure and mortality (odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.02-1.19, p = .02; OR: 1.08, 95% CI: 1.02-1.16, p = .04; respectively). Chemokines are easily detected by current methods. In the era of personalized medicine, urinary CCL2:Cr can be considered as a factor providing complementary information regarding risk of graft failure or increased mortality.
Sections du résumé
BACKGROUND
Chemokines (chemotactic cytokines) are small proteins which are engaged in many pathophysiological processes, including inflammation and homeostasis. In recent years, application of chemokines in transplant medicine was intensively studied. The aim of this study was to determine the utility of urinary chemokines CCL2 (C-C motif ligand 2) and CXCL10 (C-X-C motif chemokine ligand 10) in prognosis of 5-year graft failure and mortality post 1-year protocol biopsy in renal transplant recipients.
METHODS
Forty patients who had a protocol biopsy 1 year after renal transplantation were included. Concentrations of CCL2 and CXCL10 in urine with reference to urine creatinine were measured. All patients were under the supervision of one transplant center. Long-term outcomes within 5 years after 1-year posttransplant biopsy were analyzed.
RESULTS
Urinary CCL2:Cr at the time of biopsy was significantly increased in patients who died or had graft failure. CCL2:Cr was proven to be a significant predictor of 5-year graft failure and mortality (odds ratio [OR]: 1.09, 95% confidence interval [CI]: 1.02-1.19, p = .02; OR: 1.08, 95% CI: 1.02-1.16, p = .04; respectively).
CONCLUSION
Chemokines are easily detected by current methods. In the era of personalized medicine, urinary CCL2:Cr can be considered as a factor providing complementary information regarding risk of graft failure or increased mortality.
Identifiants
pubmed: 37382267
doi: 10.1002/iid3.901
pmc: PMC10281015
doi:
Substances chimiques
CCL2 protein, human
0
Chemokine CCL2
0
Creatinine
AYI8EX34EU
Ligands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e901Informations de copyright
© 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Références
Am J Transplant. 2021 Aug;21(8):2824-2832
pubmed: 33346917
Transplant Proc. 2013 May;45(4):1431-4
pubmed: 23726589
Int J Mol Sci. 2017 Aug 03;18(8):
pubmed: 28771176
Front Med (Lausanne). 2022 Jun 06;9:842419
pubmed: 35733857
Kidney Int. 2002 Nov;62(5):1875-83
pubmed: 12371992
J Clin Invest. 2021 Feb 1;131(3):
pubmed: 33290282
FEBS J. 2018 Aug;285(16):2944-2971
pubmed: 29637711
World J Transplant. 2019 Oct 28;9(6):123-133
pubmed: 31750089
Clin Biochem. 2016 Mar;49(4-5):355-62
pubmed: 26238260
Nat Rev Nephrol. 2014 Apr;10(4):215-25
pubmed: 24445740
Transplantation. 2016 Sep;100(9):1988-96
pubmed: 27548845
Kidney Int. 2002 Jul;62(1):311-8
pubmed: 12081593
Immunol Invest. 2017 Apr;46(3):251-262
pubmed: 27960564
Expert Opin Emerg Drugs. 2022 Jun;27(2):151-167
pubmed: 35715978
Singapore Med J. 2015 Jan;56(1):7-10
pubmed: 25640093
Int Immunopharmacol. 2021 Dec;101(Pt B):107598
pubmed: 34233864
J Clin Med. 2021 Aug 17;10(16):
pubmed: 34441931
J Transplant. 2019 Apr 8;2019:7245142
pubmed: 31093367
Ren Fail. 2008;30(4):345-52
pubmed: 18569905
Kidney Int. 2018 Nov;94(5):964-973
pubmed: 30049474
Int J Mol Sci. 2022 Jun 05;23(11):
pubmed: 35682996
Clin Chim Acta. 2011 Nov 20;412(23-24):2022-30
pubmed: 21851811
Expert Rev Proteomics. 2016 Jun;13(6):609-26
pubmed: 27232439
Front Immunol. 2020 Mar 31;11:483
pubmed: 32296423
Biomed Res Int. 2014;2014:482438
pubmed: 24971332
Kidney Int. 2000 Jun;57(6):2285-98
pubmed: 10844599
Transplant Rev (Orlando). 2012 Oct;26(4):280-90
pubmed: 22902496
Curr Opin Nephrol Hypertens. 2016 Jan;25(1):42-9
pubmed: 26625862
Int J Mol Sci. 2019 Sep 10;20(18):
pubmed: 31510053
Med Clin North Am. 2016 May;100(3):487-503
pubmed: 27095641
J Biol Chem. 2019 Oct 25;294(43):15650-15661
pubmed: 31455633
Transplantation. 2011 Oct 27;92(8):878-82
pubmed: 21876477
J Am Soc Nephrol. 2018 Dec;29(12):2775-2776
pubmed: 30420419
BMJ Open. 2019 Apr 11;9(4):e024908
pubmed: 30975673
Mediators Inflamm. 2020 Feb 5;2020:6194864
pubmed: 32089645
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Soc Nephrol. 2017 Aug;28(8):2498-2510
pubmed: 28270413
J Interferon Cytokine Res. 2009 Jun;29(6):313-26
pubmed: 19441883
Front Immunol. 2017 Nov 23;8:1432
pubmed: 29218043
Am J Transplant. 2016 May;16(5):1352-7
pubmed: 26696524
Pol Arch Intern Med. 2019 Sep 30;129(9):592-597
pubmed: 31389404
Can J Surg. 2021 Dec 21;64(6):E669-E676
pubmed: 34933944
Curr Opin Organ Transplant. 2012 Feb;17(1):20-5
pubmed: 22157320
J Am Soc Nephrol. 2002 Oct;13(10):2585-9
pubmed: 12239249
Inflamm Res. 2017 May;66(5):425-432
pubmed: 28246678
Kidney Int. 2002 Oct;62(4):1160-70
pubmed: 12234286
J Am Soc Nephrol. 2015 Nov;26(11):2840-51
pubmed: 25948873
Clin Lab Med. 2008 Sep;28(3):441-54, vii
pubmed: 19028262
Am J Transplant. 2014 Sep;14(9):2126-36
pubmed: 25307039
J Leukoc Biol. 2019 Jan;105(1):81-92
pubmed: 30376187
Pediatr Transplant. 2018 Aug;22(5):e13205
pubmed: 29733487
Nephrol Dial Transplant. 2020 Feb 1;35(2):198-203
pubmed: 31089695